Rhamy Zeid

Company: Nexo Therapeutics

Job title: Vice President, Head of Biology

Seminars:

Panel Discussion: : Examining Partner & Investor Perspectives to Fulfil the Future Opportunities of Covalent Drug Discovery & Development 10:15 am

What is investible when considering the covalency programs/platforms? What do investors look for when investing in covalent pipelines? Is a particular target or indication of interest? How to secure interest from collaboration partners and discussing how assets are considered versus platformsRead more

day: Conference Day Two

Covalent Fragment-Based Ligand Discovery to Drug Refractory Targets 5:00 pm

How can covalent fragment-based ligand discovery be leveraged to tackle so-called undruggable targets? What are the advantages of a target-centric approach to covalent fragment-based ligand discovery? What approaches (biochemical and cell-based) can be deployed to progress covalent fragment starting points to mature lead molecules within a drug discovery campaign? Read more

day: Conference Day One